Cipla Limited (CIPLA) — Board Meeting | 30 October 2025(3 announcements)

Cipla's board approved a planned leadership transition effective April 1, 2026. Achin Gupta, Global Chief Operating Officer, will succeed Umang Vohra as Managing Director & Global Chief Executive Officer for a 5-year term through March 31, 2031. Vohra, who led Cipla since 2016, expressed his intention not to seek re-appointment. Gupta, who joined Cipla in 2021 and became GCOO in February 2025, drove strong India business growth and expanded chronic therapies reach. Ms Meera Vanjari will replace AS Kumar as Global General Counsel effective April 1, 2026. Shareholder approval is required for Gupta's MD appointment.

Cipla's board approved a planned management succession effective April 1, 2026. Achin Gupta, Global Chief Operating Officer, will succeed Umang Vohra as Managing Director & Global Chief Executive Officer for a 5-year term through March 2031, subject to shareholder approval. Vohra, MD & GCEO since 2016, will not seek re-appointment upon completing his current term on March 31, 2026. Additionally, Ms Meera Vanjari was appointed Global General Counsel effective April 1, 2026, succeeding Mr AS Kumar. Gupta brings over two decades of leadership experience, having joined Cipla in 2021 and driving strong growth in India operations and strategic global partnerships.

Cipla Limited's Q2 FY2025-26 consolidated revenue reached ₹7,589.44 crores with net profit of ₹1,353.37 crores. Operating cash flow declined 34.5% YoY to ₹1,345.34 crores, while the company paid ₹1,292.40 crores in dividends. A material contingent liability of ₹2,011 crores (NPPA drug pricing demand) remains unprovisioned pending favorable resolution. The board approved unaudited results with limited review by Walker Chandiok & Co. LLP on October 30, 2025.